Red Biotechnology Market Size, Share & Trends Report

Red Biotechnology Market (2025 - 2030) Size, Share & Trends Analysis Report By Product, By End Use (Academic Research Institutes, CMOs & CROs, Pharmaceutical & Biotechnology Companies, Others), By Region, And Segment Forecasts

Market Segmentation

Red Biotechnology Product Outlook (Revenue in USD Billion, 2018 - 2030)
- Monoclonal antibodies
- Polyclonal antibodies
- Recombinant proteins
- Vaccines
- Cell-based immunotherapy products
- Gene therapy products
- Cell therapy products
- Tissue-engineered products
- Stem cells
- Cell culture
- Viral vector
- Enzymes
- Kits and reagents
- Animal models
- Molecular diagnostics
- Other
Red Biotechnology End Use Outlook (Revenue in USD Billion, 2018 - 2030)
- Academic research institutes
- CMOs & CROs
- Pharmaceutical & biotechnology companies
- Others
Red Biotechnology Regional Outlook (Revenue, USD Billion, 2018 - 2030)
- North America
  - North America Product Outlook (Revenue in USD Billion, 2018 - 2030)
    - Monoclonal antibodies
    - Polyclonal antibodies
    - Recombinant proteins
    - Vaccines
    - Cell-based immunotherapy products
    - Gene therapy products
    - Cell therapy products
    - Tissue-engineered products
    - Stem cells
    - Cell culture
    - Viral vector
    - Enzymes
    - Kits and reagents
    - Animal models
    - Molecular diagnostics
    - Others
  - North America End Use Outlook (Revenue in USD Billion, 2018 - 2030)
    - Academic research institutes
    - CMOs & CROs
    - Pharmaceutical & biotechnology companies
    - Others
  - U.S.
    - U.S. Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - U.S. End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & biotechnology companies
      - Others
  - Canada
    - Canada Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - Canada End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - Mexico
    - Mexico Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Other
    - Mexico End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & biotechnology companies
      - Others
- Europe
  - Europe Product Outlook (Revenue in USD Billion, 2018 - 2030)
    - Monoclonal antibodies
    - Polyclonal antibodies
    - Recombinant proteins
    - Vaccines
    - Cell-based immunotherapy products
    - Gene therapy products
    - Cell therapy products
    - Tissue-engineered products
    - Stem cells
    - Cell culture
    - Viral vector
    - Enzymes
    - Kits and reagents
    - Animal models
    - Molecular diagnostics
    - Others
  - Europe End Use Outlook (Revenue in USD Billion, 2018 - 2030)
    - Academic research institutes
    - CMOs & CROs
    - Pharmaceutical & Biotechnology Companies
    - Others
  - Germany
    - Germany Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Other
    - Germany End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - UK
    - UK Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - UK End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - France
    - France Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - France End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - Italy
    - Italy Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - Italy End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - Spain
    - Spain Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - Spain End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - Denmark
    - Denmark Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - Denmark End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - Sweden
    - Sweden Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - Sweden End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - Norway
    - Norway Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - Norway End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
- Asia Pacific
  - Asia Pacific Product Outlook (Revenue in USD Billion, 2018 - 2030)
    - Monoclonal antibodies
    - Polyclonal antibodies
    - Recombinant proteins
    - Vaccines
    - Cell-based immunotherapy products
    - Gene therapy products
    - Cell therapy products
    - Tissue-engineered products
    - Stem cells
    - Cell culture
    - Viral vector
    - Enzymes
    - Kits and reagents
    - Animal models
    - Molecular diagnostics
    - Others
  - Asia Pacific End Use Outlook (Revenue in USD Billion, 2018 - 2030)
    - Academic research institutes
    - CMOs & CROs
    - Pharmaceutical & Biotechnology Companies
    - Others
  - China
    - China Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - China End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - Japan
    - Japan Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - Japan End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - India
    - India Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - India End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - Thailand
    - Thailand Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - Thailand End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - South Korea
    - South Korea Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - South Korea End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - Australia
    - Australia Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - Australia End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
- Latin America
  - Latin America Product Outlook (Revenue in USD Billion, 2018 - 2030)
    - Monoclonal antibodies
    - Polyclonal antibodies
    - Recombinant proteins
    - Vaccines
    - Cell-based immunotherapy products
    - Gene therapy products
    - Cell therapy products
    - Tissue-engineered products
    - Stem cells
    - Cell culture
    - Viral vector
    - Enzymes
    - Kits and reagents
    - Animal models
    - Molecular diagnostics
  - Others
  - Latin America End Use Outlook (Revenue in USD Billion, 2018 - 2030)
    - Academic research institutes
    - CMOs & CROs
    - Pharmaceutical & Biotechnology Companies
    - Others
  - Brazil
    - Brazil Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - Brazil End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - Argentina
    - Argentina Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - Argentina End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
- Middle East and Africa
  - Middle East and Africa Product Outlook (Revenue in USD Billion, 2018 - 2030)
    - Monoclonal antibodies
    - Polyclonal antibodies
    - Recombinant proteins
    - Vaccines
    - Cell-based immunotherapy products
    - Gene therapy products
    - Cell therapy products
    - Tissue-engineered products
    - Stem cells
    - Cell culture
    - Viral vector
    - Enzymes
    - Kits and reagents
    - Animal models
    - Molecular diagnostics
    - Others
  - Middle East and Africa End Use Outlook (Revenue in USD Billion, 2018 - 2030)
    - Academic research institutes
    - CMOs & CROs
    - Pharmaceutical & Biotechnology Companies
    - Others
  - South Africa
    - South Africa Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - South Africa End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - Saudi Arabia
    - Saudi Arabia Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - Saudi Arabia End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - UAE
    - UAE Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - UAE End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others
  - Kuwait
    - Kuwait Product Outlook (Revenue in USD Billion, 2018 - 2030)
      - Monoclonal antibodies
      - Polyclonal antibodies
      - Recombinant proteins
      - Vaccines
      - Cell-based immunotherapy products
      - Gene therapy products
      - Cell therapy products
      - Tissue-engineered products
      - Stem cells
      - Cell culture
      - Viral vector
      - Enzymes
      - Kits and reagents
      - Animal models
      - Molecular diagnostics
      - Others
    - Kuwait End Use Outlook (Revenue in USD Billion, 2018 - 2030)
      - Academic research institutes
      - CMOs & CROs
      - Pharmaceutical & Biotechnology Companies
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments